Cooperative Brachytherapy | 2 Mers Seas Zeeën

CoBra

You are here

Cooperative Brachytherapy

Priority Axis

Technological and Social Innovation

Specific objective

Technological Innovation

Lead partner

Université de Lille

Start Date

01/01/2018

End Date

30/09/2022

Project budget

3 867 030

ERDF amount

2 320 218

ERDF rate

60%

    About

    Common challenge

    The common challenge addressed by the CoBra project was related to cancer control plans. In fact, the WHO estimated 345,000 European men were diagnosed with prostate cancer in 2012, representing 15% of the cancers diagnosed in men. With an estimated estimated 72 000 deaths in 2012 in Europe, prostate cancer is the fifth leading cause of death from cancer in men (source: http://globocan.iarc.fr). 
    The CoBra project dealt with technological innovation for diagnosis and treatment of localised cancers, more specifically those involving prostate and other soft tissue, with the aim of enhancing patients’ quality of life and reducing cancer mortality. 

    Main Achievements

    The Cobra project came to an end in September 2022. One of the main achievements of the CoBra project is a novelty prototype of the MR-robot for real-time biopsy and brachytherapy interventions. The development of the MR-robot started in 2020, during the start of the covid-19 period, from a joint cooperation between academic and industrial partners. The presence of observer partners, such as in the consortium from in and out the 2 Seas area facilitated the implementation of the project outputs, because they provided facilities that have been integrated or tested with the MR-robot from 2020 to 2022. A set of tests and real interventions have been realized in 2021 and 2022 thanks to the involvement of all the partners and observers of the project. This allowed the increase of the technological readiness level of the main outputs of the project and gave a prospective entry to the market after the end of the project, marked by tests on animal prostate organs. This achievement has been obtained through joint innovation between 2 Seas actors on the diagnosis and the treatment of cancers. 
    Next, A joint approach allowed the realisation of a socio-economic impacts study (2020) of the CoBra project’s innovation with promising results, enhancing coherence in the diagnosis and treatment of prostate cancers in the 2 Seas area. This helped to prepare the future deployment of CoBra technology in rural areas in order to reduce the gaps of disparity to access to the cancer healthcare. 
    In addition, the communication and dissemination events contributed to raising awareness of the CoBra robotic solution in Europe and abroad thanks to such event as: MedFIT 2020 in Lille, The Hamlyn symposium on medical robotics 2021 organized by Imperial college of London and ESTRO 2022 in Copenhagen. The actual results of the CoBra project can serve in developing other concepts of mini-invasive robots for earlier screening of local cancers such as liver and pancreas.

    Testimonial

    The main advantages of the CoBra solution are its high-field MR-compatibility, real-time adaptation, precision, automation, and time efficiency, all of which contribute to overall performance in diagnosis and treatment of localised cancers. We see this could potentially benefit or patients primarily because MRI offers much better soft tissue visualisation, we can much more clearly see the lesion and that leads to the potential to boost the dose with the brachytherapy treatments using focal therapy or indeed to reduce the number of cores that are being taken during the prostate biopsy procedure.

    Partnership

    Partners

    Centre Oscar Lambret

    Delft University of Technology

    University of Portsmouth

    Eurasanté

    DEMCON advanced mechatronics Enschede B.V.

    Société d'Accélération du Transfert de Technologie, Nord France (SATT-Nord)

    Portsmouth Hospitals NHS Trust

    DEMCON advanced mechatronics Delft B.V.

    Oncovet Clinical Research

    Outputs

    Output title
    Type
    Target
    URL / Download
    31/12/2021

    CoBra

    Theme: Technological innovationHealth care

    Common technological platforms for diagnosis and treatment of cancers

    Type: Prototype
    Target: SMEs /enterprises
    30/06/2021

    CoBra

    Theme: Health care

    Feasibility Study for Technology Transfer

    Type: Feasibility study
    Target: Universities, research and training centres
    31/12/2020

    CoBra

    Theme: Technological innovationHealth care

    Common software platforms for diagnosis and treatment of cancers

    Type: e-infrastructure/online tool
    Target: Health institutions